Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients.

Background: Cocaine- and amphetamine-regulated transcript (CART) peptide is a candidate neuropeptide as a biomarker for major depressive disorder (MDD) because of its effects on emotion and distribution covering brain areas involved in the pathophysiology of MDD symptoms. However, it is unknown whet...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Affective Disorders Vol. 232; pp. 134 - 139
Autores principales: Yoon, Hyung Shin, Hattori, Kotaro, Sasayama, Daimei, Kunugi, Hiroshi
Formato: research Journal Article
Publicado: Elsevier B.V. May2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128516678&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 128516678
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01650327
        3M9
      jtl: Journal of Affective Disorders
      issn: 01650327
      maglogo: N
    pubinfo:
      dt: May2018
      vid: 232
      pid: 1004
      pub: Elsevier B.V.
    artinfo:
      ui:
        128516678
        128516678
        NLM29486339
        128516678
        10.1016/j.jad.2018.02.039
        NLM29486339
        128516678
      ppf: 134
      ppct: 5
      formats:
      tig:
        atl: Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients.
      aug:
        au:
          Yoon, Hyung Shin
          Hattori, Kotaro
          Sasayama, Daimei
          Kunugi, Hiroshi
        affil: Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, OgawaHigashi, Kodaira, Tokyo 187-8502, Japan
      sug:
        subj:
          Nerve Tissue Proteins Cerebrospinal Fluid
          Neurotransmitter Agents Cerebrospinal Fluid
          Depression Cerebrospinal Fluid
          Human
          Antidepressive Agents Therapeutic Use
          Middle Age
          Female
          Depression Psychosocial Factors
          Psychological Tests
          Adult
          Male
          Immunoassay
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Hamilton Rating Scale for Depression
          Middle Aged: 45-64 years
          Adult: 19-44 years
          Female
          Male
      ab: Background: Cocaine- and amphetamine-regulated transcript (CART) peptide is a candidate neuropeptide as a biomarker for major depressive disorder (MDD) because of its effects on emotion and distribution covering brain areas involved in the pathophysiology of MDD symptoms. However, it is unknown whether CART peptide levels are altered in the cerebrospinal fluid (CSF) of patients with MDD patients and are correlated with MDD symptoms.Methods: Subjects were 24 patients with MDD and 25 healthy controls matched for age, gender and ethnicity (Japanese). We measured CSF CART levels by a commercially available immunoassay kit and analyzed the relationships of the levels with antidepressant dose and symptoms assessed with the 21 item Hamilton Depression Rating Scale (HAMD-21).Results: CSF CART levels were significantly decreased in the patients than in the controls (p < 0.05). In MDD patient group, the CART levels had a negative correlation with antidepressant dose (imipramine-equivalent dose) (ρ = -0.55, p < 0.01) and significantly decreased in antidepressant-treated group (AD-treated group) compared to controls (p < 0.05). CSF CART levels showed significant negative correlations with psychomotor retardation, somatic anxiety, and general somatic symptoms (all p < 0.05) and a positive correlation with obsessive and compulsive symptoms (p < 0.05).Limitations: In our analysis, all classes of antidepressants were combined together and the effects of medication use in a longitudinal manner did not confirm.Conclusions: We report for the first time that CSF CART peptide levels are reduced in patients with MDD compared with healthy controls. The CART levels showed negative correlations with antidepressant dose and some symptoms, supporting the possibility that CART peptide is involved in the development of depressive symptoms.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N